ReviewDrugs2018
Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.Neuropsychopharmacology reports · 2020Trial
- Safety and Effectiveness of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD in Japan: An Interim Analysis of Post-Marketing Surveillance.Advances in therapy · 2026Observational
- A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time.Fukushima journal of medical science · 2026Article
- Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications.Basic & clinical pharmacology & toxicology · 2025Review
- Unraveling Attention-Deficit/Hyperactivity Disorder Etiology: Current Challenges and Future Directions in Treatment.NeuroSci · 2025Review
- Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.Journal of child and adolescent psychopharmacology · 2024Observational
- Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review.Neurology and therapy · 2022Review
- Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010-2019.Journal of attention disorders · 2022Article
- Pharmacotherapy in pediatric obesity: current evidence and landscape.Current opinion in endocrinology, diabetes, and obesity · 2021Review
- Visualizing Neuropharmacological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder Using Functional Near-Infrared Spectroscopy.Frontiers in neuroergonomics · 2021Article
- Influence of executive functions on the self-reported health-related quality of life of children with ADHD.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Use of Lisdexamfetamine to Treat Obesity in an Adolescent with Severe Obesity and Binge Eating.Children (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lisdexamfetamine dimesylate (lisdexamfetamine; Elvanse
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.